Health Catalyst, Inc. (HCAT)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-29
Research Workspace
Put HCAT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Cash from operations improves to at least $18.5M in 2026-Q1: Comparison needs review.
View ThesisRevenue is contracting — down about 8% over the past year.
View GrowthManagement screens weak on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 70% in its worst 12-month stretch.
View RiskHCAT’s core AI-driven technology transformation needs to revive growth despite weak recent performance. Revenue fell 13% year over year in Q2 FY2026, which missed consensus on GAAP earnings. HCAT trades at 22× P/E versus a 25× peer median. The market prices in more growth than our forecast, leaving expectations full. The next-quarter miss probability is 49%, and the cash-flow pillar comparison needs review. Peer multiples imply a price about 3% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. HCAT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering HCAT (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare HCAT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HCAT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put HCAT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Strategic transformation focusing on core AI-driven technology
Analysts cutting targets indicates growth risks affecting strategic transformation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

New CEO aligns with strategic transformation goals.
